CY1119871T1 - Στερεη μορφη αλατος της aλφa-6-mpeg6-o- υδροξυκωδονης ως αγωνιστες οπιοειδων και χρησεις αυτων - Google Patents

Στερεη μορφη αλατος της aλφa-6-mpeg6-o- υδροξυκωδονης ως αγωνιστες οπιοειδων και χρησεις αυτων

Info

Publication number
CY1119871T1
CY1119871T1 CY20181100121T CY181100121T CY1119871T1 CY 1119871 T1 CY1119871 T1 CY 1119871T1 CY 20181100121 T CY20181100121 T CY 20181100121T CY 181100121 T CY181100121 T CY 181100121T CY 1119871 T1 CY1119871 T1 CY 1119871T1
Authority
CY
Cyprus
Prior art keywords
solid
hydroxykodone
agonors
mpeg6
alpha
Prior art date
Application number
CY20181100121T
Other languages
English (en)
Inventor
Patricia Andres
Yogesh DATAR
Ramakrishna GADIRAJU
Bruce Andrew Kowalczyk
Gabriel Christian KUKLIS
Mahmoud Mirmehrabi
Nicholas PASCHALIDES
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of CY1119871T1 publication Critical patent/CY1119871T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Στο παρόν παρέχονται ορισμένες στερεές μορφές οπιοειδών αγωνιστών. Μέθοδοι για την παρασκευή στερεών μορφών, μέθοδοι χρήσης των στερεών μορφών και φαρμακευτικές συνθέσεις που περιέχουν τις στερεές μορφές παρέχονται επίσης στο παρόν.
CY20181100121T 2012-10-30 2018-02-01 Στερεη μορφη αλατος της aλφa-6-mpeg6-o- υδροξυκωδονης ως αγωνιστες οπιοειδων και χρησεις αυτων CY1119871T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261720259P 2012-10-30 2012-10-30
US201361791894P 2013-03-15 2013-03-15
PCT/US2013/067273 WO2014070745A1 (en) 2012-10-30 2013-10-29 Solid salt form of alpha-6-mpeg6-o-hydroxycodone as opioid agonists and uses thereof

Publications (1)

Publication Number Publication Date
CY1119871T1 true CY1119871T1 (el) 2018-06-27

Family

ID=49674367

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100121T CY1119871T1 (el) 2012-10-30 2018-02-01 Στερεη μορφη αλατος της aλφa-6-mpeg6-o- υδροξυκωδονης ως αγωνιστες οπιοειδων και χρησεις αυτων

Country Status (23)

Country Link
US (2) US9682988B2 (el)
EP (2) EP2914599B1 (el)
JP (2) JP6384964B2 (el)
KR (1) KR20150076175A (el)
CN (2) CN110615796A (el)
AU (2) AU2013338098B2 (el)
CA (1) CA2886276A1 (el)
CY (1) CY1119871T1 (el)
DK (1) DK2914599T3 (el)
EA (1) EA029512B1 (el)
ES (1) ES2651689T3 (el)
HK (2) HK1213549A1 (el)
HR (1) HRP20180315T1 (el)
HU (1) HUE038161T2 (el)
IL (1) IL238529A0 (el)
LT (1) LT2914599T (el)
ME (1) ME02971B (el)
MX (1) MX367773B (el)
PL (1) PL2914599T3 (el)
PT (1) PT2914599T (el)
RS (1) RS56898B1 (el)
SI (1) SI2914599T1 (el)
WO (1) WO2014070745A1 (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10512644B2 (en) * 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
WO2014070745A1 (en) * 2012-10-30 2014-05-08 Nektar Therapeutics Solid salt form of alpha-6-mpeg6-o-hydroxycodone as opioid agonists and uses thereof
CA3071261A1 (en) * 2017-07-27 2019-01-31 Inheris Biopharma, Inc. Oral tablet formulations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800334A (en) 1993-06-17 1998-09-01 Wilk; Peter J. Intrapericardial assist device and associated method
US6096337A (en) 1996-06-10 2000-08-01 Spireas; Spiridon Liquisolid systems and methods of preparing same
ES2341510T3 (es) 1998-08-13 2010-06-21 Cima Labs Inc. Microemulsiones como formas farmaceuticas solidas para la administracion oral.
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
WO2002081477A1 (fr) * 2001-03-30 2002-10-17 Toray Industries, Inc. Derives morphinane 7-substitues et leur utilisation medicinale
WO2002080918A1 (fr) * 2001-04-02 2002-10-17 Toray Industries, Inc. Agent therapeutique ou prophylactique en cas de miction frequente ou d'incontinence urinaire
PT1436012T (pt) 2001-10-18 2018-03-27 Nektar Therapeutics Conjugados poliméricos de antagonistas de opióides
JP2005053744A (ja) 2003-08-05 2005-03-03 Dsl Japan Co Ltd 高吸油性非晶質シリカ粒子
US20050245557A1 (en) * 2003-10-15 2005-11-03 Pain Therapeutics, Inc. Methods and materials useful for the treatment of arthritic conditions, inflammation associated with a chronic condition or chronic pain
NZ572252A (en) 2006-04-21 2011-09-30 Nektar Therapeutics Stereoselective reduction of a morphinone
PT2134371E (pt) * 2007-03-12 2015-04-16 Nektar Therapeutics Conjugados agonistas de opióide-oligómero
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
CA2734333A1 (en) 2008-09-16 2010-03-25 Nektar Therapeutics Pegylated opioids with low potential for abuse
KR101788886B1 (ko) * 2009-07-21 2017-10-20 넥타르 테라퓨틱스 올리고머-오피오이드 효능제 컨주게이트
WO2011088140A1 (en) * 2010-01-12 2011-07-21 Nektar Therapeutics Pegylated opioids with low potential for abuse and side effects
DK2621496T4 (en) * 2010-09-30 2019-03-18 Astrazeneca Ab Crystalline NALOXOL-PEG CONJUGATE
EP2606879A1 (en) * 2011-12-21 2013-06-26 Hexal AG Multiple unit pellet tablet formulation comprising an opioid
WO2014070745A1 (en) * 2012-10-30 2014-05-08 Nektar Therapeutics Solid salt form of alpha-6-mpeg6-o-hydroxycodone as opioid agonists and uses thereof

Also Published As

Publication number Publication date
AU2018201297A1 (en) 2018-03-15
EP3327022A1 (en) 2018-05-30
EP2914599A1 (en) 2015-09-09
EA201590853A1 (ru) 2015-08-31
PL2914599T3 (pl) 2018-05-30
US9682988B2 (en) 2017-06-20
KR20150076175A (ko) 2015-07-06
CA2886276A1 (en) 2014-05-08
HRP20180315T1 (hr) 2018-03-23
RS56898B1 (sr) 2018-04-30
CN104755481A (zh) 2015-07-01
HUE038161T2 (hu) 2018-09-28
JP2018111718A (ja) 2018-07-19
HK1248224A1 (zh) 2018-10-12
SI2914599T1 (en) 2018-01-31
US20150284402A1 (en) 2015-10-08
US20170226119A1 (en) 2017-08-10
HK1213549A1 (zh) 2016-07-08
PT2914599T (pt) 2018-01-08
AU2013338098A1 (en) 2015-04-09
CN110615796A (zh) 2019-12-27
MX2015005510A (es) 2015-09-07
WO2014070745A1 (en) 2014-05-08
ES2651689T3 (es) 2018-01-29
ME02971B (me) 2018-07-20
DK2914599T3 (en) 2017-12-18
LT2914599T (lt) 2018-02-12
JP2015535260A (ja) 2015-12-10
EA029512B1 (ru) 2018-04-30
JP6384964B2 (ja) 2018-09-05
EP2914599B1 (en) 2017-11-22
AU2013338098A8 (en) 2015-05-21
IL238529A0 (en) 2015-06-30
AU2013338098B2 (en) 2018-03-15
MX367773B (es) 2019-09-05

Similar Documents

Publication Publication Date Title
CY1121129T1 (el) Αναστολεις toy fgfr4 πυριμιδινης
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
PH12019500176A1 (en) Heterocyclic compounds and ther uses
MX2019011926A (es) Metodos utiles en la sintesis de analogos de halicondrina b.
CY1123953T1 (el) Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης
EA201591748A1 (ru) Модуляторы p2x7
AU2013225533A8 (en) Amido spirocyclic amide and sulfonamide derivatives
UY34602A (es) ?Derivados de bencimidazolil- e imidazopiridinil-metilamina?
EA201991715A1 (ru) Композиции, содержащие антитело к pdl1
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
MX2019002979A (es) Formulaciones de anticuerpos.
EA201391285A1 (ru) Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена
EA201590731A1 (ru) Антитела к гемагглютинину и способы применения
EA201600124A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
CY1120759T1 (el) Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης
EA201591451A1 (ru) Модуляторы flap
MX2015012416A (es) Compuestos heterociclicos y sus usos.
UA116889C2 (uk) Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc)
EA201590932A1 (ru) Композиции, содержащие вортиоксетин и донепезил
CL2017000587A1 (es) Derivados de tetrahidroquinolina como inhibidores de bromodominio
CY1117210T1 (el) Παραγωγα 2-οξο-1-ιμιδαζολιδινυλ ιμιδαζοθειαδιαζολης
CY1119871T1 (el) Στερεη μορφη αλατος της aλφa-6-mpeg6-o- υδροξυκωδονης ως αγωνιστες οπιοειδων και χρησεις αυτων
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба
CY1119984T1 (el) Σταθεροποιημενη αμορφη μορφη αγομελατινης, μια μεθοδος για την παρασκευη της και φαρμακευτικες συνθεσεις που την περιεχουν